Back

Bristol-Myers Squibb Company

Ticker: BMY ISIN: US1101221083
Add to portfolio Portfolio analysis in 2min
Stock Large-cap Dividend payer Trading above 200-day average Near 52-week high
Market cap
$117.46B
P/E
16.11
Forward P/E
9.12
Profit margin
15.01%
Revenue growth QoQ
2.60%
Div. yield
4.51%
Beta
0.24
$67.92 0.95%
Price as of 2026-08-25 · NYSE

Performance by timeframe

Rolling returns
1 Month +8.57%
6 Months +13.21%
1 Year +50.77%
5 Years +4.59% p.a.+25.16%
10 Years +5.10% p.a.+64.41%
Since inception +4.65% p.a.+210.91%
Calendar year returns
YTD +30.17%
2025 +0.11%
2024 +15.81%
2023 -26.14%
2022 +18.98%
2021 +2.88%

Key stats

Market cap
117.46B
P/E
16.11
Dividend yield
4.51%
Beta
0.24
52-week range
41.46 - 62.25
50-day MA
57.09
200-day MA
53.80
Section 1

Business overview

Company profile data from fundamentals.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Sector Healthcare
Industry Drug Manufacturers - General
Country United States
Exchange NYSE
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE 38.73%
ROA 10.69%
Profit margin 15.01%
Operating margin 33.04%
PEG ratio 1.49
Revenue/share TTM 23.82
Revenue TTM 48.48B
EBITDA 18.97B
Gross profit TTM 34.90B
Beta 0.24

Valuation

Trailing P/E 16.11
Forward P/E 9.12
P/B 5.85
P/S 2.42
EV/EBITDA 10.23
EV/Revenue 3.16

ESG Scores

Total ESG 29.2
Environment 3.8
Social 18.8
Governance 14.0
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 6.31
Quarterly earnings growth 9.20%
Revenue TTM 48.48B
Reported quarters 119
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Dividend yield 4.51%
Forward annual div. yield 5.62%
Dividend per share 2.5000
Payout ratio 36.85%
Ex-dividend date 2025-10-03
Next dividend date 2026-08-03
Split factor 1000000:951777
Last split date 2001-08-07
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price $53.00
Analyst rating 3.3704

Ownership & short interest

Shares outstanding 2.04B
Shares float 2.03B
Institutional ownership 82.79%
Insider ownership 7.20%
Short ratio 3.46
Short % of float 1.94%

Details

Instrument metadata and source update timestamps.

Symbol BMY
Name Bristol-Myers Squibb Company
Asset type STOCK
Exchange NYSE
Currency USD
ISIN US1101221083
Country USA
Code + exchange BMY.NYSE
Last price date 2026-06-26
Fundamentals updated 2026-06-29

The information provided on this platform is for informational purposes only and should not be considered as financial or investment advice. Insightfolio does not provide investment advice, personalized recommendations, or guidance regarding the purchase, holding, or sale of financial assets. The tools and content are intended for educational purposes only and are not tailored to individual circumstances, financial needs, or objectives.

Insightfolio assumes no liability for the accuracy, completeness, or reliability of the information presented. Users are solely responsible for verifying the information and making independent decisions based on their own research and careful consideration. Use of the platform should not replace consultation with qualified financial professionals.

Investments involve risks. Users should be aware that the value of investments may fluctuate and that past performance is not an indicator of future results. Investment decisions should be based on personal financial goals, risk tolerance, and independent evaluation of relevant information.

Insightfolio does not endorse or guarantee the suitability of any particular financial product, security, or strategy. Any projections, forecasts, or hypothetical scenarios presented on the platform are for illustrative purposes only and are not guarantees of future outcomes.

By accessing the services, information, or content offered by Insightfolio, users acknowledge and agree to these terms of the disclaimer. If you do not agree to these terms, please do not use our platform.

Instrument logos provided by Elbstream.